pLenti6/V5-p53_R175H Citations (10)
Originally described in: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW Neoplasia. 2008 May . 10(5):450-61. PubMed
Articles Citing pLenti6/V5-p53_R175H
| Articles |
|---|
| Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. George SH, Milea A, Sowamber R, Chehade R, Tone A, Shaw PA. Oncogene. 2015 Mar 23. doi: 10.1038/onc.2015.62. PubMed |
| P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. J Cell Biol. 2016 Apr 11;213(1):81-95. doi: 10.1083/jcb.201510002. Epub 2016 Apr 4. PubMed |
| ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. Oncogenesis. 2016 Sep 12;5(9):e259. doi: 10.1038/oncsis.2016.60. PubMed |
| Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Sci Rep. 2019 Mar 26;9(1):5195. doi: 10.1038/s41598-019-41352-5. PubMed |
| Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20. PubMed |
| Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW. Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3. PubMed |
| ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Lakshmanan I, Chaudhary S, Vengoji R, Seshacharyulu P, Rachagani S, Carmicheal J, Jahan R, Atri P, Chirravuri-Venkata R, Gupta R, Marimuthu S, Perumal N, Rauth S, Kaur S, Mallya K, Smith LM, Lele SM, Ponnusamy MP, Nasser MW, Salgia R, Batra SK, Ganti AK. Mol Oncol. 2021 Jul;15(7):1866-1881. doi: 10.1002/1878-0261.12956. Epub 2021 May 1. PubMed |
| Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. Dash S, Yoder S, Mesa T, Smith A, Cen L, Eschrich S, Armaiz-Pena GN, Monteiro ANA. Sci Rep. 2021 Jul 12;11(1):14334. doi: 10.1038/s41598-021-93506-z. PubMed |
| Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. Menendez D, Anand JR, Murphy CC, Bell WJ, Fu J, Slepushkina N, Buehler E, Martin SE, Lal-Nag M, Nitiss JL, Resnick MA. Oncotarget. 2022 Feb 14;13:332-346. doi: 10.18632/oncotarget.28195. eCollection 2022. PubMed |
| Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma. Haagsma J, Kolendowski B, Buensuceso A, Valdes YR, DiMattia GE, Shepherd TG. Sci Rep. 2023 Jul 14;13(1):11424. doi: 10.1038/s41598-023-38609-5. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.